As described in the study with rapamycin and Akt inhibitor, GSK690693, inhibition of the mTOR pathway may increase insulin resistance and possibly reduce β-cell function, necessitating vigilant glucose monitoring and active intervention to control hyperglycaemia (El-Salem et al, 2007; Crouthamel et al, 2009). The gene discussed is AKT1; the disease is Hyperglycemia.